Imatinib mesylate--a new oral targeted therapy.
Savage
David G
DG
Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Antman
Karen H
KH
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D001549:Benzamides; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D006918:Hydroxyurea / Q000191:economics / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D012509:Sarcoma / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D017479:Receptors, Platelet-Derived Growth Factor; D006918:Hydroxyurea